Lotiglipron
Lotiglipron is a non-peptide GLP-1 receptor agonist which was under development by Pfizer as a weight loss drug.
≈ 1 min read
Lotiglipron. encyclopegia.org, snapshot enwiki-001330084634. /a/lotiglipron
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Lotiglipron is a non-peptide GLP-1 receptor agonist which was under development by Pfizer as a weight loss drug. However, it was withdrawn from development in June 2023, after early stage clinical trials showed elevated liver enzymes which could indicate potential for liver toxicity.
See also
Danuglipron Orforglipron
Text derived from https://en.wikipedia.org/w/index.php?oldid=1330084634 under CC BY-SA 4.0; modifications have been made.